[{"address1": "9, Rue de Bitbourg", "city": "Luxembourg", "zip": "1273", "country": "Luxembourg", "website": "https://www.alvotech.com", "industry": "Drug Manufacturers - Specialty & Generic", "industryKey": "drug-manufacturers-specialty-generic", "industryDisp": "Drug Manufacturers - Specialty & Generic", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.", "fullTimeEmployees": 1012, "companyOfficers": [{"maxAge": 1, "name": "Mr. Vilhelm Robert Wessman", "age": 56, "title": "Founder, CEO & Executive Chairman", "yearBorn": 1969, "fiscalYear": 2024, "totalPay": 2323000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Linda  Jonsdottir", "age": 47, "title": "Chief Financial Officer", "yearBorn": 1978, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Joseph E. McClellan", "age": 51, "title": "Chief Operating Officer", "yearBorn": 1974, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Benedikt  Stefansson", "title": "Vice President of Investor Relations & Global Communications", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tanya  Zharov", "age": 58, "title": "General Counsel", "yearBorn": 1967, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Sarah  Macleod", "title": "Head of Global Communications", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kathryn  Gunnarsson", "title": "Senior Vice President of Global Talent & People Experience", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Anthony M. Maffia III", "title": "Chief Quality & Regulatory Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Balaji Venkataramanan Prasad M.D.", "title": "Chief Strategy Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Johann G. Johannsson", "title": "Executive Vice President of Capital Markets and M&A", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 4.95, "open": 4.9, "dayLow": 4.86, "dayHigh": 5.01, "regularMarketPreviousClose": 4.95, "regularMarketOpen": 4.9, "regularMarketDayLow": 4.86, "regularMarketDayHigh": 5.01, "payoutRatio": 0.0, "beta": 0.114, "trailingPE": 21.391304, "forwardPE": 14.328984, "volume": 213452, "regularMarketVolume": 213452, "averageVolume": 613449, "averageVolume10days": 438590, "averageDailyVolume10Day": 438590, "bid": 3.58, "ask": 6.29, "bidSize": 2, "askSize": 2, "marketCap": 1533077632, "fiftyTwoWeekLow": 4.32, "fiftyTwoWeekHigh": 13.44, "allTimeHigh": 18.0, "allTimeLow": 4.32, "priceToSalesTrailing12Months": 2.673895, "fiftyDayAverage": 5.1222, "twoHundredDayAverage": 7.900775, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 2715398144, "profitMargins": 0.12122, "floatShares": 106071113, "sharesOutstanding": 311601154, "sharesShort": 2057424, "sharesShortPriorMonth": 3202404, "sharesShortPreviousMonthDate": 1764288000, "dateShortInterest": 1767139200, "sharesPercentSharesOut": 0.0066000004, "heldPercentInsiders": 0.61766, "heldPercentInstitutions": 0.058920003, "shortRatio": 3.34, "shortPercentOfFloat": 0.0173, "impliedSharesOutstanding": 311601154, "bookValue": -0.589, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": 69499000, "trailingEps": 0.23, "forwardEps": 0.34336, "enterpriseToRevenue": 4.736, "enterpriseToEbitda": 42.933, "52WeekChange": -0.62949103, "SandP52WeekChange": 0.14799047, "quoteType": "EQUITY", "currentPrice": 4.92, "targetHighPrice": 90.0, "targetLowPrice": 5.0, "targetMeanPrice": 22.16667, "targetMedianPrice": 10.0, "recommendationKey": "none", "numberOfAnalystOpinions": 6, "totalCash": 42848000, "totalCashPerShare": 0.143, "ebitda": 63248000, "totalDebt": 1282161024, "quickRatio": 0.543, "currentRatio": 1.421, "totalRevenue": 573350016, "revenuePerShare": 1.981, "returnOnAssets": 0.0198, "grossProfits": 318742016, "freeCashflow": -84850000, "operatingCashflow": -26486000, "revenueGrowth": 0.106, "grossMargins": 0.55592996, "ebitdaMargins": 0.11031, "operatingMargins": -0.02623, "financialCurrency": "USD", "symbol": "ALVO", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "postMarketTime": 1768604951, "regularMarketTime": 1768597201, "exchange": "NGM", "messageBoardId": "finmb_693209405", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "marketState": "CLOSED", "fiftyDayAverageChange": -0.20219994, "fiftyDayAverageChangePercent": -0.039475214, "twoHundredDayAverageChange": -2.9807749, "twoHundredDayAverageChangePercent": -0.37727627, "priceToBook": -8.353141, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2022-06-16", "cryptoTradeable": false, "shortName": "Alvotech", "longName": "Alvotech", "regularMarketChangePercent": -0.606055, "regularMarketPrice": 4.92, "regularMarketDayRange": "4.86 - 5.01", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 613449, "fiftyTwoWeekLowChange": 0.5999999, "fiftyTwoWeekLowChangePercent": 0.13888887, "fiftyTwoWeekRange": "4.32 - 13.44", "fiftyTwoWeekHighChange": -8.5199995, "fiftyTwoWeekHighChangePercent": -0.63392854, "fiftyTwoWeekChangePercent": -62.949104, "earningsTimestamp": 1773867600, "earningsTimestampStart": 1773867600, "earningsTimestampEnd": 1773867600, "earningsCallTimestampStart": 1763038800, "earningsCallTimestampEnd": 1763038800, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": 0.23, "epsForward": 0.34336, "epsCurrentYear": -0.07722, "priceEpsCurrentYear": -63.714066, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1655386200000, "postMarketChangePercent": 0.6097507, "postMarketPrice": 4.95, "postMarketChange": 0.029999733, "regularMarketChange": -0.0299997, "trailingPegRatio": null, "__fetch_time": "2026-01-17"}]